Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Remitly Global Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while Remitly Global Inc trades at $23.77 (market cap $4.97B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6× Remitly Global Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | RELY | |
|---|---|---|
Market Cap | $29.60B | $4.97B |
Sector | Health | Technology |
52-Week High | $491.22 | $25.93 |
52-Week Low | $205.48 | $12.20 |
Enterprise Value | $27.56B | $4.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
